JAMA· 2021Q1· Review
Diagnosis and Treatment of Multiple Sclerosis
- 1,173citations
- Q1SCImago
- 2021year
Short summary
Disease-modifying therapies (DMTs) for multiple sclerosis (MS) reduce annualized relapse rates by 29%-68% compared to placebo or active comparators, with nine classes available for relapsing-remitting and secondary progressive MS, and one for primary progressive MS.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Pathology and Forensic Medicine
Pathology and Forensic MedicineMedicine